Literature DB >> 15076199

Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension.

Olga V Fedorova1, Mark I Talan, Natalia I Agalakova, Edward G Lakatta, Alexei Y Bagrov.   

Abstract

OBJECTIVES: NaCl loading of Dahl salt-sensitive rats (DS) stimulates marinobufagenin (MBG), an alpha1 Na/K-ATPase (NKA) isoform ligand. Cardiac function depends on NKA, which is regulated in part by endogenous digitalis-like ligands. Our goal was to study whether changes occur in MBG and endogenous ouabain (EO) production during cardiac remodelling in hypertensive DS, and whether these are associated with changes in myocardial NKA isoforms and sensitivity to MBG and ouabain.
METHODS: Changes in MBG and EO levels, changes in myocardial NKA isoform composition, and sensitivity to endogenous ligands during development of cardiac hypertrophy and the transition to heart failure were studied in DS rats with an 8% NaCl intake.
RESULTS: The animals developed compensated left ventricular hypertrophy after 4 weeks, which progressed to heart failure at 9-12 weeks. The hypertrophic stage was associated with increased plasma MBG levels (mean +/- SEM of 1.22 +/- 0.22 versus 0.31 +/- 0.03 nmol/l; P < 0.01), increased sensitivity of NKA to MBG, and an increased abundance of alpha1 NKA. Plasma levels of EO did not change, and the sensitivity of NKA to ouabain decreased. The transition to heart failure was accompanied by a decrease in alpha1 NKA, a reduction in plasma MBG, and decreased sensitivity of NKA to MBG. In addition, an increased abundance of ouabain-sensitive alpha3 NKA, a three-fold rise in plasma EO (1.01 +/- 0.13 versus 0.27 +/- 0.06 nmol/l), and a seven-fold increase in the ouabain sensitivity of NKA compared with controls were observed.
CONCLUSIONS: During cardiac hypertrophy and the transition to heart failure, a shift in endogenous NKA ligands production is linked to a shift in myocardial NKA isoforms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076199     DOI: 10.1097/00004872-200402000-00025

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  13 in total

1.  Proinflammatory Effects of Cardiotonic Steroids Mediated by NKA α-1 (Na+/K+-ATPase α-1)/Src Complex in Renal Epithelial Cells and Immune Cells.

Authors:  Fatimah K Khalaf; Prabhatchandra Dube; Andrew L Kleinhenz; Deepak Malhotra; Amira Gohara; Christopher A Drummond; Jiang Tian; Steven T Haller; Zijian Xie; David J Kennedy
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

2.  Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure.

Authors:  David J Kennedy; Kevin Shrestha; Brendan Sheehey; Xinmin S Li; Anuradha Guggilam; Yuping Wu; Michael Finucan; Alaa Gabi; Charles M Medert; Kristen Westfall; Allen Borowski; Olga Fedorova; Alexei Y Bagrov; W H Wilson Tang
Journal:  Circ Heart Fail       Date:  2015-08-14       Impact factor: 8.790

Review 3.  Endogenous digitalis: pathophysiologic roles and therapeutic applications.

Authors:  Alexei Y Bagrov; Joseph I Shapiro
Journal:  Nat Clin Pract Nephrol       Date:  2008-06-10

Review 4.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

5.  Role of mitochondrial dysfunction in cardiac glycoside toxicity.

Authors:  Ting Liu; David A Brown; Brian O'Rourke
Journal:  J Mol Cell Cardiol       Date:  2010-07-08       Impact factor: 5.000

6.  Aortic Fibrosis, Induced by High Salt Intake in the Absence of Hypertensive Response, is Reduced by a Monoclonal Antibody to Marinobufagenin.

Authors:  Yulia N Grigorova; Ondrej Juhasz; Valentina Zernetkina; Kenneth W Fishbein; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov
Journal:  Am J Hypertens       Date:  2015-09-07       Impact factor: 2.689

Review 7.  The Na+K+-ATPase Inhibitor Marinobufagenin and Early Cardiovascular Risk in Humans: a Review of Recent Evidence.

Authors:  Michél Strauss; Wayne Smith; Olga V Fedorova; Aletta E Schutte
Journal:  Curr Hypertens Rep       Date:  2019-04-12       Impact factor: 5.369

8.  Monoclonal Antibody to Marinobufagenin Downregulates TGFβ Profibrotic Signaling in Left Ventricle and Kidney and Reduces Tissue Remodeling in Salt-Sensitive Hypertension.

Authors:  Yongqing Zhang; Wen Wei; Victoria Shilova; Natalia N Petrashevskaya; Valentina I Zernetkina; Yulia N Grigorova; Courtney A Marshall; Rachel C Fenner; Elin Lehrmann; William H Wood; Kevin G Becker; Edward G Lakatta; Alexei Y Bagrov; Olga V Fedorova
Journal:  J Am Heart Assoc       Date:  2019-10-02       Impact factor: 6.106

9.  Marinobufagenin and left ventricular mass in young adults: The African-PREDICT study.

Authors:  Michél Strauss; Wayne Smith; Ruan Kruger; Wen Wei; Olga V Fedorova; Aletta E Schutte
Journal:  Eur J Prev Cardiol       Date:  2018-07-11       Impact factor: 7.804

10.  High Salt Diet Affects Renal Sodium Excretion and ERRα Expression.

Authors:  Dan Wang; Yang Wang; Fu-Qiang Liu; Zu-Yi Yuan; Jian-Jun Mu
Journal:  Int J Mol Sci       Date:  2016-04-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.